New York State Teachers Retirement System Has $384,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

New York State Teachers Retirement System lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 23.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,474 shares of the specialty pharmaceutical company’s stock after buying an additional 2,350 shares during the period. New York State Teachers Retirement System’s holdings in Collegium Pharmaceutical were worth $384,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of COLL. Pacer Advisors Inc. increased its holdings in Collegium Pharmaceutical by 68.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock valued at $66,938,000 after purchasing an additional 883,380 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Collegium Pharmaceutical in the first quarter valued at $7,506,000. Assenagon Asset Management S.A. increased its holdings in Collegium Pharmaceutical by 178.1% in the third quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after purchasing an additional 272,565 shares during the period. Marshall Wace LLP increased its holdings in Collegium Pharmaceutical by 668.2% in the fourth quarter. Marshall Wace LLP now owns 307,030 shares of the specialty pharmaceutical company’s stock valued at $7,123,000 after purchasing an additional 267,065 shares during the period. Finally, BlackRock Inc. grew its holdings in Collegium Pharmaceutical by 4.6% during the 2nd quarter. BlackRock Inc. now owns 6,078,319 shares of the specialty pharmaceutical company’s stock worth $130,623,000 after acquiring an additional 266,330 shares during the period.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $34.77 on Friday. The stock has a market capitalization of $1.14 billion, a P/E ratio of 29.47 and a beta of 1.03. The company has a current ratio of 1.17, a quick ratio of 1.10 and a debt-to-equity ratio of 2.48. The firm’s 50 day moving average is $36.82 and its 200 day moving average is $30.72. Collegium Pharmaceutical, Inc. has a 12 month low of $20.83 and a 12 month high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The business had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. On average, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on COLL. Jefferies Financial Group reiterated a “hold” rating and set a $37.00 price target (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Needham & Company LLC reiterated a “buy” rating and set a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Truist Financial increased their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Monday, February 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $39.00 target price (up from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. Finally, StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 29th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.